Book a Meeting

Non-Fucosylated Anti-Human 58P1D12 (58P1D12) Therapeutic Antibody (CAT#: BioBet-489ZP) Datasheet

Target
58P1D12
Isotype
IgG
Description
This is a non-fucosylated ADCC-Enhanced anti-58P1D12 therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced 58P1D12 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
58P1D12
Full Name
58P1D12
Background
A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
Alternative Names
58P1D12
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
58P1D12
Host
Human
Species Reactivity
Human
Description
58P1D12 antibody are particularly useful in cancer diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibody are useful in the treatment, diagnosis, and/or prognosis of ovarian and other cancers, to the extent 58P1D12 is also expressed or overexpressed in these other cancers.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany